Articles related to CAR-T THERAPY
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.
Hematology/Oncology February 5th 2024
Exploring How CAR T-Cell Therapy May Help More Patients
Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.
Hematology/Oncology January 22nd 2024
FDA Puts Clinical Hold on Three CARsgen Therapeutics CAR-T Candidates
CARsgen Therapeutics faces a critical juncture as the FDA places a clinical hold on three of its key CAR-T cell therapy candidates, highlighting the paramount importance of manufacturing standards in the realm of advanced oncology treatments.
Hematology/Oncology January 16th 2024
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.
Hematology/Oncology September 11th 2023
Study Finds Hallmarks of T Cell Exhaustion Within Hours of Tumor Exposure
The rapid exhaustion of T cells upon encountering a tumor, as revealed in a recent study, challenges existing theories and may have profound implications for cancer immunotherapies. Explore the findings to understand how this discovery could influence the future of personalized treatment.
Oncology, Medical August 14th 2023